Filing Flows

Filing Flows › Sarepta Therapeutics (SRPT) › Next earnings date

Sarepta Therapeutics (SRPT) earnings: missed the estimate

Sarepta Therapeutics (SRPT) reported on Nov 5, 2026 and missed the EPS estimate: $0.13 against $0.36 (-63.6%). Revenue was $381M for Q3 2026, -4% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result−63.6% vs estimate
Beat rate60%

The last report

Sarepta Therapeutics reported revenue of $381M for the third quarter 2026 (-4% Y/Y), net loss $28.5M: Pmo Products $240M, Elevidys $83.5M, Other revenues $57.6M. How it makes money → · Every quarter →

Sarepta Therapeutics: EPS against the estimate, last 5 reportsSarepta Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.37−$0.13Nov 25−$0.77−$3.58Feb 26$1.05$3.16May 26$0.49$0.64Aug 26$0.36$0.13Nov 26
Latest (Nov 26): Estimate $0.36, Reported $0.13.
SRPT: the stock's move on each reportSRPT: the stock's move on each reportAug 5, 2026+2.4%May 6, 2026-4.5%Feb 25, 2026-7.4%Nov 3, 2025-32.5%

Sarepta Therapeutics' latest quarter

Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Sarepta Therapeutics beat earnings?

Sarepta Therapeutics (SRPT) reported on Nov 5, 2026 and missed the EPS estimate: $0.13 against $0.36 (-63.6%).

When does SRPT report earnings?

The next date is not set yet.

Does Sarepta Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.